Macrophage targeting in cancer.
Martha Lopez-YrigoyenLuca CassettaJeffery W PollardPublished in: Annals of the New York Academy of Sciences (2020)
Tumorigenesis is not only determined by the intrinsic properties of cancer cells but also by their interactions with components of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the TME. During initial stages of tumor development, macrophages can either directly promote antitumor responses by killing tumor cells or indirectly recruit and activate other immune cells. As genetic changes occur within the tumor or T helper 2 (TH 2) cells begin to dominate the TME, TAMs begin to exhibit an immunosuppressive protumor phenotype that promotes tumor progression, metastasis, and resistance to therapy. Thus, targeting TAMs has emerged as a strategy for cancer therapy. To date, TAM targeting strategies have focused on macrophage depletion and inhibition of their recruitment into the TME. However, these strategies have shown limited therapeutic efficacy, although trials are still underway with combination therapies. The fact that macrophages have the potential for antitumor activity has moved the TAM targeting field toward the development of TAM-reprogramming strategies to support this antitumor immune response. Here, we discuss the various roles of TAMs in cancer therapy and their immunosuppressive properties, as well as implications for emerging checkpoint inhibitor-based immunotherapies. We review state-of-the-art TAM-targeting strategies, focusing on current ones at the preclinical and clinical trial stages that aim to reprogram TAMs as an oncological therapy.
Keyphrases
- cancer therapy
- drug delivery
- clinical trial
- immune response
- adipose tissue
- dendritic cells
- prostate cancer
- induced apoptosis
- randomized controlled trial
- risk assessment
- cell proliferation
- dna damage
- gene expression
- regulatory t cells
- oxidative stress
- young adults
- climate change
- signaling pathway
- human health
- phase ii
- radical prostatectomy
- squamous cell